Cardiff Oncology shares plunge after Q2 earnings miss
Investing.com -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) stock surged 32.9% premarket following the publication of a peer-reviewed article validating the disease-modifying potential of its experimental antibody treatment for serious skin conditions.
The article, published in the Journal of Dermatological Treatment, confirms that PC111, a first-in-class human anti-Fas Ligand monoclonal antibody, can prevent blister formation in various models of pemphigus, a rare autoimmune skin disorder. The research builds on previous award-winning work and introduces new data from a humanized mouse model where PC111 significantly reduced disease activity.
Beyond pemphigus, the research highlights PC111’s potential in treating Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), a life-threatening dermatological emergency. Unlike current treatments that rely on systemic immunosuppression, PC111 targets the final step in disease pathology, potentially offering a faster-acting and safer therapeutic profile.
"This new publication further validates our conviction that PC111 has the potential to transform the treatment landscape for pemphigus and SJS/TEN," said Amir Reichman, CEO of Scinai. The company noted that the combined market opportunity for both indications exceeds $1 billion annually.
Scinai holds an option to acquire Pincell, the company that developed PC111. If exercised, the companies plan to advance the treatment through IND-enabling studies and into clinical development. PC111 has already received orphan drug designation in the EU, with similar status being pursued in the U.S.
The development program includes several strategic advantages, including expert leadership from the drug’s inventor, multiple peer-reviewed publications supporting its efficacy, and potential non-dilutive funding through a €15 million grant that could cover up to 80% of development costs through IND readiness.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.